Effect of Ethanolic Extract of *Ipomoea staphylina* Leaves on Glycogen and Carbohydrate Metabolizing Enzymes in Streptozotocin Induced Diabetic Rats

P. Shobana Devi*[1] and M. Shabana Begum[2]

A B S T R A C T

Herbs provide a new efficient alternative compound for treating hyperglycemic conditions. Recently studies proved that herbs impart the huge amount of antidiabetic compounds. In our studies, it is evaluating the effect of *Ipomoea staphylina* (ISEE) leaves extract on streptozotocin (STZ) induced diabetic rats. ISEE (200 mg/kg bw) was administered orally for 45 days to diabetic animals. Plasma glucose, insulin, carbohydrate metabolizing enzymes, glycogen content was determined in diabetic rats. The levels were restored to normal by the administration of ISEE. The results of this study revealed the antidiabetic effect of ISEE on STZ induced diabetic models. Finally, this study also proved the application of ISEE as promising alternate and complementary pharmacological agent against diabetes and its complications.

Key words: Antidiabetic studies, Carbohydrates, Metabolizing enzymes, *Ipomoea staphylina*, Streptozotocin

Diabetes mellitus (DM) is a long-term disorder characterized by inherited and or pancreatic insufficiency in insulin secretion. Due to insulin insufficiency the condition hyperglycemia occurs in fasting and postprandial condition linked with ketosis and in rigorous condition loss of protein occurs [1]. DM is attaining a pandemic figure throughout the world and the state of affairs in developing nations is worsening day by day [2]. According to the international diabetes federation (IDA) report, the number of diabetic patients is expected to increase from 171 million in year 2000 to 366 million or more by the year 2030.

A hyperglycemia-associated mechanism induces many dysfunctions. These include increased polyol pathway flux, altered cellular redox state, increased lipid profile and accelerated reactive oxygen species (ROS) [3]. Suffering from such a pandemic metabolic disease associated with hyperglycemia, patients with diabetes mellitus are known to have various changes in metabolic pathway including carbohydrate metabolism. Defects in regulation of carbohydrate metabolism and reliable efforts of the physiological systems to correct the imbalance in carbohydrate metabolism place an overexertion on the endocrine system, which leads to the deterioration of endocrine control. Persistent deterioration of endocrine control exacerbates the metabolic disturbances and leads primarily to hyperglycemia. Gluconeogensis and glycolysis are the

important mechanism for the maintenance of normoglycemic status [4]. This presents a moving therapeutic target that requires different agents to address the different features of the disease [5]. Management of diabetes with conventional treatment is not possible without adverse effect and high economic input [6]. Traditional medicinal plants and their active biomolecules play a major role in the management of diabetes mellitus from the beginning of the last century [7]. Thus, a suitable antioxidant therapy would benefit in diabetes apart from traditional antidiabetic treatment. In recent years, considerable focus have been given to an intensive search for novel type of antioxidants present in plants and plant derived products for treating diabetes and related complications [8].

Ipomoea staphylina is a wide spread rambler belong to the family convolvulaceae. It is a persistent, timbered and tonsured hedge plant of pink colored flowers. A review of literature determines the various activities include antiulcer and anti-inflammatory, α-amylase, α-glucosidase and 5-lipoxygenase inhibition of *Ipomoea staphylina* [9]. It is a traditional medicine for treating respiratory problems, purgative, digestive disorders, anti-helmintic, and bronchitis. In advanced research of *Ipomoea staphylina* two bioactive compounds namely sitosteryl-3-O-β-Dglucoside and chiro deoxy inositol were isolated [10]. Till now, there is no scientific research to assess the anti-diabetic activity of leaves of IS in STZ induced diabetic animals. So, the present study was carried out to determine the effect of antidiabetic activity of *Ipomoea staphylina* leaves in STZ induced diabetic rats by assessing the carbohydrate metabolic enzymes in serum, muscle and kidneys of STZ induced diabetes rats.

*P. Shobana Devi

shobirose2013@gmail.com

[1-2]Department of Biochemistry, Muthayammal College of Arts and Science, Rasipuram - 637 408, Namakkal District, Tamil Nadu, India

MATERIALS AND METHODS

Res. Jr. of Agril. Sci. (Mar-Apr) **12**(2): 453–457

454

Sample collection

Fresh IS leaves were collected and taxonomically authenticated by the botanist Dr. S. John Britto at The Rapinat Herbarium, where the specimen was deposited with the voucher number RVP 001.

Preparation of IS leaf extracts

Fresh IS leaves were collected and cleaned with distilled water and allowed to dry. Then powdered using a mechanical grinder and stored in a sterile container at 4°C until future use. 30 g of IS leaf powder was extracted with 200 ml of solvent ethanol at room temperature for 24hrs and filtered using Whatman No.1 filter paper to remove extractable substances, at every 3 hours interval. The combined extracts were then evaporated at 40°C to dryness. The dried extracts were stored at 4°C until further use.

Animals

Male albino wistar rats weighing approximately 160-200g were purchased and used for the study. The animals were maintained under standard conditions of humidity, temperature (25 ± 2ºC) and light (12 h light/dark). They were acclimatized to animal house conditions and were fed on a commercial pellet rat chow (AVM Cattle Feeds, Coimbatore, Tamil Nadu) and water *ad libitum*. Experimental animals were handled according to the university and institutional Legislation, regulated by the Committee for the purpose of Control and Supervision of Experiments on Animals (CPCSEA), Ministry of Social Justice and Empowerment, Government of India. All the protocol to execute this study was approved by Institutional ethical committee with the approval number. Albino wistar rats weighing 180-200g was overnight fasted and induced with STZ (55 mg/kg BW) by intraperitoneal (IP) injection. Citrate buffer with pH 4.5 was used for STZ preparation. The increased glucose level (>240 mg/dl) in blood determined at 72 hours and on 7th day after STZ administration confirms hyperglycemia. After induction of diabetes profitably the experimental animals were divided into four groups with six rats' minimum in each group.

Experimental design

Group I: Control rats.
Group II: Diabetic induced rats.
Group III: Diabetic rats administered orally with *Ipomoea staphylina* ethanol extract (ISEE) of leaves (200 mg/kg body weight/rat) for 45 days
Group IV: Diabetic rats administered orally with glibenclamide (600 µg / kg body weight/rat) [11].

The rats were fasted and sacrificed with cervical decapitation overnight, following the last treatment (45 days). The blood was hoarded, and after centrifugation, the plasma was collected. Then, the glucose estimation was done. The tissues of the liver, kidney, and pancreas were directly removed from the experimental animals and kept in ice-cold containers. We are then homogenized with an appropriate buffer solution, centrifuged, and stored the supernatant. Biochemical estimates have been made inhomogeneous on the very same day of sacrifice.

Collection of plasma or serum

Weight gain regarding body weight (data not shown) and glucose level in blood was determined randomly. At the end of the study, the animals were overnight fasted, anaesthetized and sacrificed by cervical decapitation. Blood was collected with or without EDTA for plasma or serum separation respectively.

Tissue homogenate preparation

10% homogenate of kidney and muscle were prepared with 0.1 M Tri-HCl buffer, pH 7.4. The homogenate was centrifuged at 3000 rpm for 10 min at 0°C. Supernatant was separated and used for various biochemical estimations.

Biochemical estimations
Estimation of blood glucose level

Glucose level in blood was determined by method of [12]. To 10 µl of sample added 1.0 ml of working standard reagent, mixed and incubated at 37°C for 15 min. The colour developed was read at 505 nm against blank containing distilled water instead of the sample. A standard was also processed similarly. The level of glucose is expressed as mg dl^{-1}.

Assay of insulin

A plasma level of insulin was determined using kits from Bio-Merieux, RCS, Lyon, France. 25 µl of the plasma was dispensed in microwells coated with anti-insulin antibody. To this, 100 µl of the enzyme conjugate was dispensed into each well, mixed for 5 sec and incubated at 25°C for 30 min. The wells were rinsed five times with washing buffer. Then, 100 µl of solution A and then 100 µl of solution B were dispensed into each well. This was incubated for 15 min at room temperature. The reaction was stopped by adding 50 µl of 2 N HCl to each well and read at 450 nm. The values are expressed as μU ml^{-1}.

Assay of hexokinase

Tissue hexokinase was assayed by the method of [13]. To 1 ml of glucose add 0.5 ml of adenosine triphosphate (ATP), 0.1 ml of magnesium chloride, 0.4 ml of potassium dihydrogen phosphate, 0.4 ml of potassium chloride, 0.4 ml of sodium fluoride and 2.5 ml of Tris-HCl buffer and this mixture was pre-incubated at 37°C for 5 min. The reaction was initiated by the addition of 2 ml of tissue homogenate. 1 ml of the reaction mixture was immediately transferred to the tubes containing 1 ml of 10% TCA that was considered as zero time. A second aliquot was removed and deproteinized after 30 min incubation at 37°C. The protein precipitate was removed by centrifugation and the residual glucose in the supernatant was estimated.

Assay of Glucose -6- phosphatase

G-6-Pase was measured by the method of Koida and Oda [14]. To 0.7 ml of citrate buffer (0.1 mol/l, pH 6.5) add 0.3 ml of substrate (0.01mol/l) and 0.3 ml of tissue homogenate. The reaction mixture was incubated at 37°C for 1 h. The reaction of the enzyme was arrested by adding 1 ml of 10% TCA. The suspension was centrifuged and the phosphorus content of the supernatant. The supernatant was made up to a known volume. To this, 1 ml of ammonium molybdate was added followed by 0.4 ml of amino naphthol sulphonic acid (ANSA). The blue colour developed after 20 min was read at 680 nm.

Assay of Fructose-1,6-bisphosphatase

Fructose-1,6-bisphosphatase activity was measured by Gancedo and Gancedo 1971. The assay mixture in a final volume of 2 ml contained 1.2 ml of Tris-HCl buffer (0.1 mol/l, pH 7.0), 0.1 ml of substrate, 0.25 ml of magnesium chloride,

0.1 ml of potassium chloride solution, 0.25 ml of ethylene diamine tetra acetic acid (EDTA) solution and 0.1 ml of enzyme homogenate. The incubation was carried out at 37°C for 5 min. The reaction of the enzyme was arrested by the addition of 10% TCA. The suspension was centrifuged and the supernatant was used for. The supernatant was made up to a known volume. To this, 1 ml of ammonium molybdate was added followed by 0.4 ml of ANSA. The blue colour developed after 20 min was read at 680 nm.

Estimation of glycogen

Tissue glycogen was estimated by the method of [15]. The alkali extract of the tissue was prepared by digesting 50 mg of fresh tissue with 3 ml of 30% potassium hydroxide solution in boiling water bath for 15 min. The tubes were cooled and mixed with 5 ml of absolute alcohol. A drop of 1 mol/l ammonium acetate was added to precipitate glycogen and left in the freezer overnight for complete precipitation. Glycogen was collected by centrifugation at $2000 \times g$ for 20 min. The precipitate was dissolved in distilled water with the aid of heating and again the glycogen was re-precipitated with alcohol and 1mol/l ammonium acetate and centrifuged. The final precipitate was dissolved in saturated ammonium chloride solution and 4 ml of anthrone reagent was added by cooling the tubes in an ice bath. The tubes were shaken well, covered with marble caps and heated in a boiling water bath for 20 min. After cooling, the absorbance was read at 640 nm against reagent blank treated in a similar manner.

Statistical analysis

All conclusions happen to be demonstrated as Mean ± SD. in each group for six animals. All the compiled data were statistically examined utilizing SPSS10 software. Theory Hypothesis test approaches included one-way variance analysis (ANOVA) followed by the least significant difference (LSD) test. The significance level at alpha=0.05 was considered to statistical significance.

RESULTS AND DISCUSSION

The level of plasma glucose and insulin in normal and experimental animals was depicted in (Fig 1). Increased glucose ($p<0.05$) and concomitant decrease level of plasma insulin was observed in diabetic control animals. Administration of *Ipomoea staphylina* ethanol extract (ISEE) at a dose of 200 mg/kg b.w significantly altered the level of blood glucose and insulin. The (Fig 2) showed the oral glucose tolerance test in normal and experimental diabetic animals. An augmented level of blood glucose (maximum value at 60 min) in the diabetic rats was observed after glucose load and decreased to near normal levels at 120 min, whereas, in STZ induced diabetic rats, the peak increase in blood glucose level was observed even after 60 min and remained high over the next 60 min. Supplementation with ISEE as well as glibenclamide to diabetic rats elicited a significant decrease in blood glucose level at 60 min when compared with untreated diabetic rats.

Table 1 Effects of ISEE on Hexokinase and Fructose-1,6 bis Phosphatase in control and experimental animals

Groups	Hexokinase			Fructose 1,6 bis phosphatase		
	Serum	Muscle	Kidney	Serum	Muscle	Kidney
Control	18.9±2.4	0.53±0.07	0.37±0.04	44.5±1.6	21.1±1.64	30.5±1.4
Diabetic	7.08±2.0[a***]	0.34±0.02 [a***]	0.20±0.02 [a***]	63.01±2.9 [a***]	33.2±2.7 [a***]	57.7±3.1 [a***]
Diabetic + ISEE (200 mg/k.g b.w)	14.9±2.02 [b***]	0.45±0.03 [b***]	0.29±0.03 [b***]	38.4±1.2 [b***]	24.3±1.5 [b***]	34.4±3.3 [b***]
Diabetic + Glibenclamide (600 µg/k.g b.w)	15.9±1.5 [b***]	0.51±0.03 [b***]	0.33±0.01 [b***]	41.6±1.8 [b***]	22.5±1.5 [b***]	32.2±14.1 [b***]

Values are mean ± S.D, n = 6;　　[a] Significantly different from control;　　[b] Significantly different from Diabetic control ***P < 0.001
Hexokinase: µ moles of glucose phosphorylated/min/mg of protein; Fructose-1,6 bis Phosphatase: µ moles of Pi liberated/min/mg of protein

Table 2 Effects of ISEE on glucose 6-Phosphatase in control and experimental animals

Groups	Glucose 6-phosphatase	
	Serum	Kidney
Control	85.04±2.7	9.5±1.16
Diabetic	154.0±6.2[a***]	24.2±2.03 [a***]
Diabetic + ISEE (200 mg/k.g b.w)	105.1±2.8 [b***]	14.4±2.9[b***]
Diabetic + Glibenclamide (600 µg/k.g b.w)	89.3±2.7 [b***]	13.1±2.5 [b***]

Values are mean ± S.D, n = 6; [a]Significantly different from control;
[b]Significantly different from Diabetic control; ***P < 0.001;
Glucose-6-Phosphatase: µ moles of Pi liberated/min/mg of protein

The (Table 1) depicts the activities of hexokinase and fructose1-6-bis phosphatase in the normal control and experimental diabetic animals. Decreased hexokinase level and concomitant increased level of fructose1-6- bis phosphatase was observed in serum, muscle and kidneys of STZ induced diabetic animals and it was normalized after ISEE treatment and glibenclamide. (Table 2) showed the activity of glucose 6-phosphatase in serum and kidney Increased level of glucose 6-phosphatase was found in

diabetic animals. Administration of ISEE and glibenclamide decreased the activity of glucose 6-phosphatase ($P < 0.001$) in serum and kidneys of experimental diabetic rats. The glycogen content in kidney and muscle in the experimental animals was represented in (Table 3). Declined glycogen level in muscle and concomitant increased in level of kidneys were found in the diabetic condition. Administration of ISEE and standard significantly ($P < 0.05$) reversed the glycogen contents in the tissues to near normal.

Table 3 Effects of ISEE on glycogen content in control and experimental animals

Groups	Glycogen (mg/g wet tissue)	
	Serum	Kidney
Control	6.7±0.6	4.6±0.3
Diabetic	3.4±0.7[a***]	6.5±0.6 [a***]
Diabetic + ISEE (200 mg/k.g b.w)	5.4±0.7 [b**]	5.4±0.2 [b**]
Diabetic + Glibenclamide (600 µg/k.g b.w)	5.6±0.5 [b***]	5.2±0.2 [b**]

Values are mean ± S.D, n = 6; [a]Significantly different from control;
[b]Significantly different from Diabetic control
**P < 0.01, ***P < 0.001

Diabetes mellitus (DM) is characterized by persistent hyperglycemia due to progressive dysfunction of pancreatic β-cells which leads to decrease insulin secretion. DM occurs due to improper metabolism of carbohydrate with lack or insufficient insulin secretion. During diabetes, pancreatic islets are destructed and reduced the secretion of insulin which leads to hyperglycemia [16]. STZ-induced hyperglycemia in experimental rats has been commonly used one to study the effect of various hypoglycemic agents. STZ damage the pancreatic β-cells which lead to deficient insulin secretion and type 1 diabetic model [17]. STZ induction also resulted in a significant increase in the blood glucose level and reduction in plasma insulin level. The oral administration ISEE and the drug glibenclamide was halting the sustained hyperglycemia and reverting back the blood glucose and insulin levels to that of control animals.


Values are mean ± S.D, n = 6; [a] Significantly different from control; [b] Significantly different from Diabetic control *P < 0.05
Fig 1 Effects of ISEE on blood glucose and plasma insulin in control and experimental animals

Values are mean ± S.D, n = 6; [a] Significantly different from control; [b] Significantly different from Diabetic control *P < 0.05
Fig 2 Effects of ISEE on glucose tolerance in control and experimental animals (after experimental period)

Hexoinase is glucose metabolizing enzyme which play a very important role (as a glucose sensor) in secreting insulin for regulating plasma glucose levels. It is an insulin-dependent and insulin-sensitive enzyme and is almost completely inhibited or inactivated in diabetic rat liver in the absence of insulin [18]. There are many reports revealed the decreased enzymatic activity of hexokinase diabetic animals, resulting in depletion of liver and muscle glycogen [19]. This increased activity of hexokinase can cause the increased utilization of glucose for energy production [20]. In our study, decreased level of hexokinase was observed in serum, muscle and kidneys of STZ induced diabetic rats. Administration of ISEE and glibenclamide to STZ treated rats resulted in an increased activity of hexokinase.

Fructose 1,6-bisphosphatase, a vital key enzyme in gluconeogenic pathway, converts fructose-1,6-bisphosphate to fructose-6-phosphate and this is the essential step to perform reversal of glycolysis [21]. Fructose 1,6-bisphosphatase is also present in liver, kidney and muscle [22]. In gluconeogenesis, the irreversible step serves as a site for enzyme regulation. These enzyme activities were elevated in serum, muscle and kidney of experimental rats due to insulin deficiency which leads to hyperglycemic condition [23]. On administration of ISEE orally STZ induced diabetic rats significantly decreased the activities of this enzyme. This was due to the modulatory effect of ISEE against the enzyme activity by regulating cAMP or by activating metabolism of glycolysis and gluconeogenesis.

Glucose-6- phosphatase is main glucose regulating enzyme in tissue catalyzes end step that converts glucose-6-Phosphate to glucose and phosphate [24]. This enzyme plays vital role in balancing free glucose and stored glucose as glycogen. During diabetes, an increased activity of glucose-6-phosphatase was observed [25]. Activation of glucose-6-phosphatase is due to state of insulin deficiency since under normal condition insulin function as a suppressor of glucose-6-phosphatase enzyme. In the present study, increased glucose-6-phosphatase activity in diabetic rats was observed than that of normal rats and the oral feeding of ISEE and glibenclamide markedly lowered its activity. The reduction in enzyme activity corresponded to the decrease in serum glucose as less glucose was being produced and released into the blood stream [26].

Glycogen, a stored form of glucose is synthesized by the enzyme glycogen synthase. Its amount represents the activity of insulin that supports deposition of glycogen by enhancing glycogen synthase and inhibiting glycogen phosphorylase [27]. Deposition of glycogen is impaired in diabetic rats [28] in relation to insulin deficiency [29]. Diabetic rats showed a lower content of glycogen in liver and increased in kidney [30]. Lower levels of glycogen were due to the deficiency of insulin and in liver and muscle [31]. In our study, kidney glycogen content was increased and this confirmed that glucose entry under hyperglycemic state is not dependent on insulin action. This elevated deposition of glycogen causes glycosylation. Glycogen rise in kidneys was already reported [32]. On oral administration of ISEE changes the glycogen content favorably by elevating insulin action and consequently lowered glucose levels in blood.

CONCLUSIONS

Our present study determines the ISEE ability as anti-hyperglcemic effect in STZ induced diabetic rats. The effect of *Ipomoea staphylina* ethanol extract (ISEE) provides favorable effect against hyperglycemia and it was due to enhancement in the external glucose consumption, modulating glycolysis and gluconeogenesis. The beneficial effect of ISEE was comparable with standard drug, glibenclamide. Oral administration of *Ipomoea staphylina* ethanol extract (ISEE) of leaves was used for managing diabetes and prevention of diabetic complications.

LITERATURE CITED

1. Ramakrishnan P, Ramadoss D, Muthulingam P, Nedunchezhian R, Krishnamoorthy K. 2017. Antidiabetic, antihyperlipidemic, antioxidant property of *Cordia obliqua* on streptozotocin induced diabetic rats. *Journal of Young Pharmacists* 9(3): 321.
2. Toniolo A, Cassani G, Puggioni A, Rossi A, Colombo A, Onodera T, Ferrannini E. 2019. The diabetes pandemic and associated infections: suggestions for clinical microbiology. *Reviews in Medical Microbiology* 30(1): 1.
3. Evcimen ND, King GL. 2007. The role of protein kinase C activation and the vascular complications of diabetes. *Pharmacological Research* 55(6): 498-510.
4. Ashokkumar N, Pari L. 2005. Effect of N-benzoyl-D-phenylalanine and metformin on carbohydrate metabolic enzymes in neonatal streptozotocin diabetic rats. *Clinica Chimica Acta* 351(1/2): 105-113.
5. Bailey CJ. 2000. Potential new treatments for type 2 diabetes. *Trends in Pharmacological Sciences* 21(7): 259-265.
6. Srivastava Y, Venkatakrishna-Bhatt H, Verma Y, Venkaiah K, Raval BH. 1993. Antidiabetic and adaptogenic properties of *Momordica charantia* extract: an experimental and clinical evaluation. *Phytotherapy Research* 7(4): 285-289.
7. Pari L, Venkateswaran S. 2003. Protective effect of *Coccinia indica* on changes in the fatty acid composition in streptozotocin induced diabetic rats. *Die Pharmazie-An International Journal of Pharmaceutical Sciences* 58(6): 409-412.
8. Fabricant DS, Farnsworth NR. 2001. The value of plants used in traditional medicine for drug discovery. *Environmental Health Perspectives* 109(Suppl 1): 69-75.
9. Firdous SM, Raju K. 2012. In vivo and in vitro anti-inflammatory activity of leaves of *Ipomoea staphylina*. *Int. Journal of Pharm. Pharm. Science* 4(5): 339-343.
10. Gupta SK, Bodakhe SH. 2013. An elevated pulse pressure: a major risk factor for cardiovascular diseases. *Asian Jr Pharm. Clin. Research* 6(5): 5-11.
11. Gancedo JM, Gancedo C. 1971. Fructose-1, 6-diphosphatase, phosphofructokinase and glucose-6-phosphate dehydrogenase from fermenting and non-fermenting yeasts. *Archiv für Mikrobiologie* 76(2): 132-138.
12. Sasaki K, Jinnai K, Gemba H, Hashimoto S, Mizuno N. 1979. Projection of the cerebellar dentate nucleus onto the frontal association cortex in monkeys. *Exp. Brain Research* 37: 193-198.
13. Kinney LaPier TL, Rodnick KJ. 2001. Effects of aerobic exercise on energy metabolism in the hypertensive rat heart. *Physical Therapy* 81(4): 1006-1017.
14. Hikaru K, Toshitsugu O. 1959. Pathological occurrence of glucose-6-phosphatase in serum in liver diseases. *Clinica Chimica Acta* 4(4): 554-561.
15. Ong KC, Khoo HE. 2000. Effects of myricetin on glycemia and glycogen metabolism in diabetic rats. *Life Sciences* 67(14): 1695-1705.
16. Zhu D, Zhang Y, Lam PP, Dolai S, Liu Y, Cai EP, Choi D, Schroer SA, Kang Y, Allister EM, Qin T. 2012. Dual role of VAMP8 in regulating insulin exocytosis and islet β cell growth. *Cell Metabolism* 16(2): 238-249.
17. Nisha P, Mini S. 2013. Flavanoid rich ethyl acetate fraction of Musa paradisiaca inflorescence down-regulates the streptozotocin induced oxidative stress, hyperglycaemia and mRNA levels of selected inflammatory genes in rats. *Journal of Functional Foods* 5(4): 1838-1847.
18. Gupta BL, Nehal M, Baquer NZ. 1997. Effect of experimental diabetes on the activities of hexokinase, glucose-6-phosphate dehydrogenase and catecholamines in rat erythrocytes of different ages. *Indian Jr. Experimental Biology* 35(7): 792.
19. Murray RK. 2000. *Harper's Biochemistry*. Edition 25th. Appleton and Lange. pp 610-617.
20. Prince PS, Menon VP, Pari L. 1997. Effect of *Syzygium cumini* extracts on hepatic hexokinase and glucose-6-phosphatase in experimental diabetes. *Phytotherapy Research: An International Journal Devoted to Medical and Scientific Research on Plants and Plant Products* 11(7): 529-531.
21. Timson DJ. 2019. Fructose 1,6-*bis*phosphatase: getting the message across. *Bioscience Reporter* 39(3): 1-5. https://doi.org/10.1042/BSR20190124
22. Tillmann H, Bernhard D, Eschrich K. 2002. Fructose-1, 6-bisphosphatase genes in animals. *Gene* 291(1/2): 57-66.
23. Aoki K, Saito T, Satoh S, Mukasa K, Kaneshiro M, Kawasaki S, Okamura A, Sekihara H. 1999. Dehydroepiandrosterone suppresses the elevated hepatic glucose-6-phosphatase and fructose-1, 6-bisphosphatase activities in C57BL/Ksj-db/db mice: comparison with troglitazone. *Diabetes* 48(8): 1579-1585.
24. Zhou C, Ge X, Liu B, Xie J, Chen R, Ren M. 2015. Effect of high dietary carbohydrate on the growth performance, blood chemistry, hepatic enzyme activities and growth hormone gene expression of Wuchang bream (*Megalobrama amblycephala*) at two temperatures. *Asian-Australasian Journal of Animal Sciences* 28(2): 207.
25. Venkateswaran S, Pari L. 2002. Effect of *Coccinia indica* on blood glucose, insulin and key hepatic enzymes in experimental diabetes. *Pharmaceutical Biology* 40(3): 165-170.
26. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH. 2011. Management of type 2 diabetes: new and future developments in treatment. *The Lancet* 378(9786): 182-197.
27. Pederson BA, Schroeder JM, Parker GE, Smith MW, DePaoli-Roach AA, Roach PJ. 2005. Glucose metabolism in mice lacking muscle glycogen synthase. *Diabetes* 54(12): 3466-3473.
28. Bollen M, Keppens S, Stalmans W. 1998. Specific features of glycogen metabolism in the liver. *Biochemical Journal* 336(1): 19-31.
29. Gannon MC, Nuttall FQ. 1997. Effect of feeding, fasting, and diabetes on liver glycogen synthase activity, protein, and mRNA in rats. *Diabetologia* 40(7): 758-763.
30. Vats V, Yadav SP, Grover JK. 2004. Ethanolic extract of *Ocimum sanctum* leaves partially attenuates streptozotocin-induced alterations in glycogen content and carbohydrate metabolism in rats. *Journal of Ethnopharmacology* 90(1): 155-160.
31. Kalaiarasi P, Pugalendi KV. 2009. Antihyperglycemic effect of 18β-glycyrrhetinic acid, aglycone of glycyrrhizin, on streptozotocin-diabetic rats. *European Journal of Pharmacology* 606(1/3): 269-273.
32. Roden M, Bernroider E. 2003. Hepatic glucose metabolism in humans—its role in health and disease. *Best Practice and Research Clinical Endocrinology and Metabolism* 17(3): 365-383.